Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

Conditions:Obesity Weight Loss, Endocrine
Therapuetic Areas:Endocrinology
Age Range:18 - 70
Start Date:November 2011
End Date:September 2017

Use our guide to learn which trials are right for you!

The primary objective of this study is to determine the influence of insulin resistance on
drug metabolism and response in obese subjects. The investigators hypothesize that expression
of adiponectin (a hormone secreted by fat tissue), and specific variants in the adiponectin
gene can predict the insulin resistance and drug response among obese subjects.

The following study will hypothesizes that insulin resistance causes changes in drug
metabolism, elimination, and effect. We will differentiate the insulin resistant phenotype
amongst obese individuals on the basis of both laboratory (fasting insulin, triglycerides,
fasting glucose) analysis, and quantitative and qualitative adiponectin expression. We will
determine the effect of insulin resistance on the pharmacokinetics and pharmacodynamics of
anesthetic induction agents and opioids, using propofol and fentanyl as examples.

Inclusion Criteria:

- Inclusion criteria include patients of adult age

- American Society of Anesthesiologists Class I, II, or III, and undergoing elective
surgical procedures requiring general anesthesia

- Body mass index greater than 35

Exclusion Criteria:

- Patients with evidence of hepatic, renal, or cardiovascular dysfunction

- History of difficult tracheal intubation, or adverse reaction to anesthesia shall be
excluded from the study

- Patients taking prescribed or over-the-counter anxiolytics, narcotics, or sleeping
aids, will also be excluded
We found this trial at
Stanford, CA
Click here to add this to my saved trials